AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.
Amlo Biosciences has raised $2.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2024.
Amlo Biosciences's investors include Future Planet Capital, Northstar Ventures, North East Fund, Ascension Life Fund, Esperante Ventures.
Amlo Biosciences is headquartered in Newcastle Upon Tyne, United Kingdom.
AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.
Amlo Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amlo Biosciences — Funding & Investors." VCBacked, December 3, 2024, https://www.vcbacked.co/company/amlo-biosciences. Accessed November 12, 2026.
VCBacked. (2024). Amlo Biosciences — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/amlo-biosciences
{{cite web |title=Amlo Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/amlo-biosciences |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Amlo Biosciences? Request a listing update